Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)

This article was originally published in The Pink Sheet Daily

Executive Summary

Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority.
Advertisement

Related Content

Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
PharmAsia News Presents: Notable Notes On Emerging Markets (Vol. 1, No. 2)
DNDi Mulls Expansion Of India Site; Set To Team With More Pharma On The Heels Of Sanofi Deal - BIO Conference
Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
Merck Invests In China Oncology Start-up BeiGene
Turkey Again Slashes Drug Prices; Manufacturers And Pharmacists Cry Foul
Sanofi-Aventis Emerging Markets Sales Exceed U.S., Europe: Emerging Markets Earnings Round Up (Part 2)
Sanofi-Aventis Emerging Markets Sales Exceed U.S., Europe: Emerging Markets Earnings Round Up (Part 2)

Topics

Advertisement
UsernamePublicRestriction

Register

PS072746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel